We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The epidemic of severe acute respiratory syndrome (SARS) has sparked a host of unexpected alliances in the global research community.

In this article, Alison Abbott reports on one such alliance, between Jiang Hua-Liang, head of the Drug Discovery and Design Center at the Shanghai Institute of Materia Medica, and Rolf Hilgenfeld, a structural biologist at the University of Lübeck in Germany.

The researchers hopes that the combination of Hilgenfeld's expertise in coronaviruses and Jiang's knowledge of using supercomputers to screen drug candidates will allow them to develop new leads for anti-SARS drugs. Their plans will be turned into a formal funding proposal to be presented to the Sino-German Centre for Science Promotion, which is jointly financed by research agencies in Germany and China.

Link to Nature article

Reference: Nature 423, 791 (2003)